Toripalimab with standard treatment for HPV-positive throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests adding a new immunotherapy drug (toripalimab) to standard chemo for HPV-positive throat cancer. It aims to see if this combination works better than chemo alone for patients whose cancer has spread to nodes but not to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have throat cancer caused by HPV type 16 (a specific virus).
- The cancer must have spread to lymph nodes in the neck or be a larger tumor, but not spread to distant organs.
- You cannot have had chemotherapy or radiation for head and neck cancer before.
- You must be healthy enough to get a standard chemo drug called cisplatin.
- You must be 18 or older and able to follow daily activities without major limitations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This early-phase study tests a lab-made treatment using your own immune cells (T cells) to target HPV-related throat cancers. It aims to reduce cancer by directing your immune system against HPV16/HPV18 and a protein called survivin.
This trial studies whether adding toripalimab (an immunotherapy drug) to standard chemo before surgery can improve outcomes for people with newly diagnosed, advanced head and neck cancer that can be surgically removed. It may help your immune system fight the cancer more effectively.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests a combination of the immunotherapy drug toripalimab with chemotherapy for women with locally advanced cervical cancer that has not been treated yet. The goal is to see if this approach can shrink tumors before standard radiation therapy.
Hear when a new Oropharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.